Going-concern and funding shortfall
The company disclosed that cash is not sufficient to fund planned operations for at least a year and it has no committed future funding.
- Scope
- Operations, R&D, and commercialization plans
- Materiality
- high
BullFrog AI Holdings, Inc.
BullFrog AI Holdings, Inc. is a U.S.-based AI/ML company focused on applying machine learning to complex biomedical data to support drug discovery and development. The company’s core platform, bfLEAP™, originated from technology developed at The Johns Hopkins University Applied Physics Laboratory and has since been expanded with additional models and tools. BullFrog AI combines software-driven analytics services with a broader strategy of partnering with biopharma companies and, longer term, acquiring drug rights and using its platform to accelerate development. The business is still early-stage and pre-commercial at scale, with limited revenue history and a continuing need for external financing to fund operations.
−5 650,9 %
18,8 %
−5 569,6 %
+79,5 %
3.85
3.85
| % | |
|---|---|
| AI/ML biomedical analytics platform | 40% bfLEAP™ and related machine-learning tools used to analyze complex medical and life-science datasets. |
| Biopharma analytical services | 35% Custom analysis engagements for drug discovery, target identification, and workflow integration. |
| Strategic collaborations | 15% Partnerships with biopharma and research organizations structured around fees, equity, or IP. |
| In-licensed drug programs | 10% Acquired or licensed drug candidates advanced using the company’s AI/ML capabilities. |
BullFrog AI sells primarily to biopharma companies that want to reduce the time, cost, and risk of drug development by...
- Biopharma collaboratorsprimary
Drug developers that buy analytical services and platform access to reduce development risk and speed decision-making.
- Clinical and preclinical drug programssecondary
Partners around in-licensed or acquired drug assets that need AI/ML support to advance candidates toward value-creating milestones.
- Research institutions and data partnerssecondary
Organizations that provide datasets, validation, or scientific collaboration to strengthen the platform and expand use cases.
- Public health and proprietary data holdersemerging
Data owners that enable new discovery workflows and improve model training and analytical depth.
BullFrog AI is headquartered in the United States and its operations are currently conducted through its U.S...
- •Headquartered and operated in the United States
- •U.S. capital markets are important for funding and liquidity
- •Scientific collaboration and data access are primarily U.S.-based
- •No disclosed country-level revenue mix in the provided excerpts
- •Geographic exposure is driven more by partner location than by sales footprint
BullFrog AI’s near-term strategy is to generate revenue through strategic relationships with biopharma companies, using...
01
Expand biopharma collaborationsshort-term
Partnership revenue is the company’s main near-term commercialization path and helps validate the platform.
02
Advance bfLEAP™ capabilitiesmedium-term
Improving the AI/ML platform increases the quality of insights and strengthens differentiation in drug discovery analytics.
03
Acquire and develop drug assetsmedium-term
Owning or licensing programs can create higher-value monetization opportunities than services alone.
BullFrog AI faces substantial going-concern and financing risk because it has limited recurring revenue and has stated...
Internal control material weakness
Management reported unremediated material weaknesses in financial reporting controls, increasing the risk of misstatement and delayed reporting.
- Scope
- Financial reporting and investor confidence
- Materiality
- high
Customer and partnership concentration
Revenue depends on a limited number of biopharma collaborations and the company has only a short commercial history.
- Scope
- Revenue stability and pipeline visibility
- Materiality
- high
AI/ML model and drug-development uncertainty
The platform must prove that its analytics improve drug-development outcomes, which is inherently uncertain and data-dependent.
- Scope
- Product adoption and asset value creation
- Materiality
- medium
Revenue recognition for collaborations and services
Can shift revenue between periods and affect comparability
Fair value measurement of non-cash consideration
Can materially affect reported revenue and other income
Internal control remediation
Affects confidence in all reported financial statement line items
Going-concern assessment
Influences investor assessment of solvency and dilution risk
JFrog Ltd
FROG · Services-Prepackaged Software
JFrog Ltd builds a software supply chain platform that helps enterprises store, secure, govern, and continuously deliver software artifacts from code to production.
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
BMP AI Technologies, Inc.
BMPA · Services-Motion Picture & Video Tape Production
Simulations Plus, Inc.
SLP · Services-Computer Integrated Systems Design
Bubblr Inc.
BBLR · Services-Computer Programming, Data Processing, Etc.
Bubblr Inc., which also operates under the Ethical Web AI name, is a U.S.-based artificial intelligence company built around patent-protected software and search technologies.
FIREFLY NEUROSCIENCE, INC.
AIFF · Services-Prepackaged Software
: 11/08/2026